Kim JS - Search Results

1

Comprehensive pharmacogenomic characterization of gastric cancer.

Sa JK, Hong JY, Lee IK, Kim JS, Sim MH, Kim HJ, An JY, Sohn TS, Lee JH, Bae JM, Kim S, Kim KM, Kim ST, Park SH, Park JO, Lim HY, Kang WK, Her NG, Lee Y, Cho HJ, Shin YJ, Kim M, Koo H, Kim M, Seo YJ, Kim JY, Choi MG, Nam DH, Lee J. Sa JK, et al. Among authors: kim jy, kim st, kim hj, kim km, kim s, kim m, kim js. Genome Med. 2020 Feb 18;12(1):17. doi: 10.1186/s13073-020-0717-8. Genome Med. 2020. PMID: 32070411 Free PMC article.

2

Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system.

Cho JH, Kim JS, Kim ST, Hong JY, Park JO, Park YS, Nam DH, Lee DW, Lee J. Cho JH, et al. Among authors: kim st, kim js. PLoS One. 2019 Apr 17;14(4):e0215080. doi: 10.1371/journal.pone.0215080. eCollection 2019. PLoS One. 2019. PMID: 30995234 Free PMC article.

3

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.

Kim JS, Kim JE, Kim K, Lee J, Park JO, Lim HY, Park YS, Kang WK, Kim ST. Kim JS, et al. Among authors: kim st, kim je, kim k. J Cancer. 2017 Aug 22;8(14):2713-2719. doi: 10.7150/jca.19458. eCollection 2017. J Cancer. 2017. PMID: 28928860 Free PMC article.

4

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.

Kim SY, Ahn T, Bang H, Ham JS, Kim J, Kim ST, Jang J, Shim M, Kang SY, Park SH, Min BH, Lee H, Kang WK, Kim KM, Park W, Lee J. Kim SY, et al. Among authors: kim st, kim km, kim j. Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788. Oncotarget. 2017. PMID: 28122360 Free PMC article.

5

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.

Lee JK, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, Cho HJ, Elliott O, Chu T, Choi SW, Rosenbloom DIS, Lee IH, Shin YJ, Kang HJ, Kim D, Kim SY, Sim MH, Kim J, Lee T, Seo YJ, Shin H, Lee M, Kim SH, Kwon YJ, Oh JW, Song M, Kim M, Kong DS, Choi JW, Seol HJ, Lee JI, Kim ST, Park JO, Kim KM, Song SY, Lee JW, Kim HC, Lee JE, Choi MG, Seo SW, Shim YM, Zo JI, Jeong BC, Yoon Y, Ryu GH, Kim NKD, Bae JS, Park WY, Lee J, Verhaak RGW, Iavarone A, Lee J, Rabadan R, Nam DH. Lee JK, et al. Among authors: kim nkd, kim st, kim km, kim d, kim sh, kim sy, kim m, kim j, kim hc. Nat Genet. 2018 Oct;50(10):1399-1411. doi: 10.1038/s41588-018-0209-6. Epub 2018 Sep 27. Nat Genet. 2018. PMID: 30262818 Free PMC article.

6

Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening.

Lim SH, Sa JK, Lee DW, Kim J, Kim ST, Park SH, Ku B, Park JO, Park YS, Lim H, Kang WK, Nam DH, Lee J. Lim SH, et al. Front Oncol. 2019 Nov 29;9:1327. doi: 10.3389/fonc.2019.01327. eCollection 2019. Front Oncol. 2019. PMID: 31850215 Free PMC article.

7

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma.

Cho J, Lee J, Kim J, Kim ST, Lee S, Kim SY, Ha SY, Park CK, Lim HY. Cho J, et al. Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009. Transl Oncol. 2016. PMID: 27751352 Free PMC article.

8

3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor.

Kim ST, Kim J, Shin S, Kim SY, Lee D, Ku B, Shin YS, Kim J, Lee J. Kim ST, et al. Oncotarget. 2017 May 30;8(22):36484-36491. doi: 10.18632/oncotarget.16883. Oncotarget. 2017. PMID: 28445128 Free PMC article.

9

Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.

Pham DH, Kim JS, Kim SK, Shin DJ, Uong NT, Hyun H, Yoon MS, Kang SJ, Ryu YJ, Cho JS, Yoon JH, Lee JS, Cho D, Lee SH, Park MH. Pham DH, et al. Among authors: kim sk, kim js. Anticancer Res. 2017 Oct;37(10):5507-5513. doi: 10.21873/anticanres.11981. Anticancer Res. 2017. PMID: 28982863

10

Immunological characterization of glioblastoma cells for immunotherapy.

Jung TY, Choi YD, Kim YH, Lee JJ, Kim HS, Kim JS, Kim SK, Jung S, Cho D. Jung TY, et al. Among authors: kim yh, kim sk, kim js, kim hs. Anticancer Res. 2013 Jun;33(6):2525-33. Anticancer Res. 2013. PMID: 23749904

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15,252 results

Search Page